Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs nVent Electric (NVT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs nVent Electric — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.88B), while nVent Electric trades at $148.5 (market cap $24.72B). The key difference: nVent Electric is far larger — about 2.8× Kymera Therapeutics Inc. Common Stock's market cap, and nVent Electric pays a 0.55% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and nVent Electric for 14 Days on average.
| KYMR | NVT | |
|---|---|---|
Market Cap | $8.88B | $24.72B |
Volume | 1,028,790 | 2,529,194 |
Sector | Health | Industrials |
52-Week High | $127.31 | $184.34 |
52-Week Low | $55.80 | $94.99 |
Typical Hold Time | 0 Days | 14 Days |
Enterprise Value | $8.27B | $26.10B |
Dividend Yield | — | 0.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NVT trades at $161.47, down 0.8% with a bullish technical outlook and strong institutional support. The company demonstrates robust earnings momentum with three consecutive quarterly beats and a 61% YTD surge driven by AI data-center demand. Recent developments include the $1.75 billion acquisition of Maverick Power and a strategic collaboration with AMD on cooling solutions for AI infrastructure, positioning NVT for continued growth in the expanding data center market.
While NVT's premium valuation (P/E 44.85) and rising competition present risks, strong analyst consensus (85% buy rating) with a $203.86 price target suggests 26% upside potential. The company's expanding AI infrastructure portfolio and solid cash flow generation support long-term growth, though investors should monitor tariff impacts and valuation compression risks in a competitive landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About nVent Electric
nVent provides electrical connection and protection solutions, including enclosures, fastening systems, and thermal management products. Its products help support electrical and industrial infrastructure across multiple end markets.
Read more on NVT →
